Tor Åge Myklebust

Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study

Melina Arnold, Mark J. Rutherford, Aude Bardot et al. · The Lancet Oncology · 2019 · 1K citations · Full text

Epidemiology, Cancer Epidemiology, Medicine +13

Transanal total mesorectal excision for rectal cancer has been suspended in Norway

Hans H. Wasmuth, Arne E. Færden, Tor Åge Myklebust et al. · British journal of surgery · 2019 · 251 citations · Full text

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial

Knut Jørgen Labori, Svein Olav Bratlie, Bodil Andersson et al. · ˜The œLancet. Gastroenterology & hepatology · 2024 · 174 citations

Surgical Oncology, Pancreatic Cancer, Gastrointestinal Oncology +6

A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations

Hege Elvebakken, Aurel Perren, Jean‐Yves Scoazec et al. · Neuroendocrinology · 2020 · 101 citations · Full text

Gastroenterology, Pathology, Surgery +24

Cancer Risk in Women Treated with Fertility Drugs According to Parity Status—A Registry-based Cohort Study

Marte Myhre Reigstad, Ritsa Storeng, Tor Åge Myklebust et al. · Cancer Epidemiology Biomarkers & Prevention · 2017 · 97 citations · Full text